{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:32:24Z","timestamp":1781897544581,"version":"3.54.5"},"reference-count":277,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.580732","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T06:09:02Z","timestamp":1605766142000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting Tau to Treat Clinical Features of Huntington's Disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Maria","family":"Masnata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shireen","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"de Rus Jacquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehwish","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/369488a0","article-title":"Altered microtubule organization in small-calibre axons of mice lacking tau protein","volume":"369","author":"Harada","year":"1994","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1523\/JNEUROSCI.5245-10.2011","article-title":"Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant","volume":"31","author":"Sydow","year":"2011","journal-title":"J Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pneurobio.2008.03.002","article-title":"Microtubule-associated protein tau in development, degeneration and protection of neurons","volume":"85","author":"Wang","year":"2008","journal-title":"Prog Neurobiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fncel.2018.00338","article-title":"Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability","volume":"12","author":"Alonso","year":"2018","journal-title":"Front Cell Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1021\/bi00552a027","article-title":"Inhibition of microtubule assembly by phosphorylation of microtubule-associated proteins","volume":"19","author":"Jameson","year":"1980","journal-title":"Biochemistry."},{"key":"B6","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1016\/S0021-9258(17)42989-9","article-title":"Phosphorylation affects the ability of tau protein to promote microtubule assembly","volume":"259","author":"Lindwall","year":"1984","journal-title":"J Biol Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/nm.3951","article-title":"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits","volume":"21","author":"Min","year":"2015","journal-title":"Nat Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm0896-871","article-title":"Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease","volume":"2","author":"Wang","year":"1996","journal-title":"Nat Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"28741","DOI":"10.1074\/jbc.271.46.28741","article-title":"The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine","volume":"271","author":"Arnold","year":"1996","journal-title":"J Biol Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0002-9440(10)63462-1","article-title":"Nitration of tau protein is linked to neurodegeneration in tauopathies","volume":"163","author":"Horiguchi","year":"2003","journal-title":"Am J Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9919","DOI":"10.1074\/jbc.M510127200","article-title":"Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and \u03b1-synuclein","volume":"281","author":"Dorval","year":"2006","journal-title":"J Biol Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/j.1460-2075.1993.tb05665.x","article-title":"Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament","volume":"12","author":"Novak","year":"1993","journal-title":"EMBO J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40478-017-0491-z","article-title":"EuroTau: towing scientists to tau without tautology","volume":"5","author":"Mudher","year":"2017","journal-title":"Acta Neuropathol Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1073\/pnas.95.13.7737","article-title":"Mutation in the tau gene in familial multiple system tauopathy with presenile dementia","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jalz.2015.02.007","article-title":"On the identification of low allele frequency mosaic mutations in the brains of Alzheimer's disease patients","volume":"11","author":"Sala Frigerio","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/alzrt137","article-title":"Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort","volume":"4","author":"Jin","year":"2012","journal-title":"Alzheimers Res Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.neurobiolaging.2007.07.013","article-title":"Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation","volume":"30","author":"Momeni","year":"2009","journal-title":"Neurobiol Aging."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1093\/hmg\/dds161","article-title":"Evidence for a role of the rare p","volume":"21","author":"Coppola","year":"2012","journal-title":"Hum Mol Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/ejhg.2014.300","article-title":"Rare variants in \u03b2-Amyloid precursor protein (APP) and Parkinson's disease","volume":"23","author":"Schulte","year":"2015","journal-title":"Eur J Hum Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1093\/hmg\/ddi241","article-title":"The H1c haplotype at the MAPT locus is associated with Alzheimer's disease","volume":"14","author":"Myers","year":"2005","journal-title":"Hum Mol Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"44994","DOI":"10.18632\/oncotarget.16690","article-title":"Meta-analysis of the association between variants in MAPT and neurodegenerative diseases","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget."},{"key":"B24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3233\/JAD-150555","article-title":"MAPT H1 haplotype is associated with late-onset Alzheimer's Disease risk in APOE\u03b54 noncarriers: results from the dementia genetics Spanish consortium","volume":"49","author":"Pastor","year":"2016","journal-title":"J Alzheimers Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fnagi.2019.00327\/full","article-title":"The MAPT H1 haplotype is a risk factor for Alzheimer's Disease in APOE \u03b54 non-carriers","volume":"11","author":"S\u00e1nchez-Juan","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"The role of tau in the pathological process and clinical expression of Huntington's disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain."},{"key":"B28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0896-6273(92)90117-V","article-title":"Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms","volume":"8","author":"Goedert","year":"1992","journal-title":"Neuron."},{"key":"B29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00418-011-0891-2","article-title":"Tangle evolution linked to differential 3- and 4-repeat tau isoform deposition: a double immunofluorolabeling study using two monoclonal antibodies","volume":"137","author":"Uchihara","year":"2012","journal-title":"Histochem Cell Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-017-0501-1","article-title":"Brainstem tau pathology in Alzheimer's disease is characterized by increase of three repeat tau and independent of amyloid \u03b2","volume":"6","author":"Uematsu","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nm.3617","article-title":"Huntington's disease is a four-repeat tauopathy with tau nuclear rods","volume":"20","author":"Fern\u00e1ndez-Nogales","year":"2014","journal-title":"Nat Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington's disease","volume":"135","author":"St-Amour","year":"2018","journal-title":"Acta Neuropathol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/brain\/aww021","article-title":"Is Huntington's disease a tauopathy?","volume":"139","author":"Gratuze","year":"2016","journal-title":"Brain."},{"key":"B34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain."},{"key":"B36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"9623","DOI":"10.1523\/JNEUROSCI.1590-19.2019","article-title":"Tau misfolding efficiently propagates between individual intact hippocampal neurons","volume":"39","author":"Hallinan","year":"2019","journal-title":"J Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nn.4328","article-title":"Neuronal activity enhances tau propagation and tau pathology in vivo","volume":"19","author":"Wu","year":"2016","journal-title":"Nat Neurosci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.neuron.2011.11.033","article-title":"Propagation of tau pathology in a model of early Alzheimer's disease","volume":"73","author":"de Calignon","year":"2012","journal-title":"Neuron."},{"key":"B40","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/ncb1901","article-title":"Transmission and spreading of tauopathy in transgenic mouse brain","volume":"11","author":"Clavaguera","year":"2009","journal-title":"Nat Cell Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"9535","DOI":"10.1073\/pnas.1301175110","article-title":"Brain homogenates from human tauopathies induce tau inclusions in mouse brain","volume":"110","author":"Clavaguera","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/brain\/awx255","article-title":"Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease","volume":"140","author":"Cisbani","year":"2017","journal-title":"Brain."},{"key":"B43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s007020050095","article-title":"Alzheimer-type lesions in Huntington's disease","volume":"105","author":"Jellinger","year":"1998","journal-title":"J Neural Transm."},{"key":"B44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ana.410030616","article-title":"Huntington disease associated with Alzheimer disease","volume":"3","author":"McIntosh","year":"1978","journal-title":"Ann Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/jnnp.48.6.530","article-title":"Late onset of Huntington's disease","volume":"48","author":"Myers","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1212\/WNL.35.2.273","article-title":"Dementia of the Alzheimer's type and Huntington's disease","volume":"35","author":"Reyes","year":"1985","journal-title":"Neurology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2004.10.031","article-title":"Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease","volume":"373","author":"Hye","year":"2005","journal-title":"Neurosci Lett."},{"key":"B48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/00005072-199701000-00007","article-title":"Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain","volume":"56","author":"Pei","year":"1997","journal-title":"J Neuropathol Exp Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1111\/j.0953-816X.2004.03365.x","article-title":"Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain","volume":"19","author":"Swatton","year":"2004","journal-title":"Eur J Neurosci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/45159","article-title":"Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration","volume":"402","author":"Patrick","year":"1999","journal-title":"Nature."},{"key":"B51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0006-8993(00)02200-9","article-title":"Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain","volume":"865","author":"Yasojima","year":"2000","journal-title":"Brain Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/hmg\/ddl437","article-title":"The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease","volume":"16","author":"Kimura","year":"2007","journal-title":"Hum Mol Genet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1471-4159.2007.05075.x","article-title":"Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between down syndrome and Alzheimer's disease","volume":"104","author":"Ryoo","year":"2008","journal-title":"J Neurochem."},{"key":"B54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","article-title":"Tau protein kinases: involvement in Alzheimer's disease","volume":"12","author":"Martin","year":"2013","journal-title":"Ageing Res Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e2206","DOI":"10.1038\/cddis.2016.104","article-title":"GSK-3\u03b2-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions","volume":"7","author":"L'Episcopo","year":"2016","journal-title":"Cell Death Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/hmg\/ddu421","article-title":"Mutant huntingtin alters tau phosphorylation and subcellular distribution","volume":"24","author":"Blum","year":"2015","journal-title":"Hum Mol Genet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1471-4159.1993.tb03603.x","article-title":"Phosphoprotein phosphatase activities in Alzheimer disease brain","volume":"61","author":"Gong","year":"1993","journal-title":"J Neurochem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/j.1460-9568.2005.04391.x","article-title":"Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation","volume":"22","author":"Liu","year":"2005","journal-title":"Eur J Neurosci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.arr.2012.06.008","article-title":"Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A","volume":"12","author":"Martin","year":"2013","journal-title":"Ageing Res Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11064-005-2483-9","article-title":"Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1","volume":"30","author":"Rahman","year":"2005","journal-title":"Neurochem Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"3","author":"Hanger","year":"2009","journal-title":"Trends Mol Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"23654","DOI":"10.1074\/jbc.m703269200","article-title":"Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis","volume":"32","author":"Hanger","year":"2007","journal-title":"J Biol Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40478-018-0557-6","article-title":"Phosphorylation of different tau sites during progression of Alzheimer's disease","volume":"6","author":"Neddens","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"B64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/hmg\/ddu456","article-title":"Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease","volume":"24","author":"Gratuze","year":"2015","journal-title":"Hum Mol Genet."},{"key":"B65","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1073\/pnas.91.12.5562","article-title":"Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease","volume":"12","author":"Alonso","year":"1994","journal-title":"PNAS."},{"key":"B66","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nm0796-783","article-title":"Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules","volume":"2","author":"Alonso","year":"1996","journal-title":"Nat Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1073\/pnas.94.1.298","article-title":"Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau","volume":"1","author":"Alonso","year":"1997","journal-title":"PNAS."},{"key":"B68","doi-asserted-by":"publisher","first-page":"5726","DOI":"10.1523\/JNEUROSCI.17-15-05726.1997","article-title":"Selective destruction of stable microtubules and axons by inhibitors of protein serine\/threonine phosphatases in cultured human neurons (NT2N Cells)","volume":"15","author":"Merrick","year":"1997","journal-title":"J Neurosci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"9647","DOI":"10.1523\/JNEUROSCI.1899-16.2016","article-title":"Soluble conformers of A\u03b2 and tau alter selective proteins governing axonal transport","volume":"37","author":"Sherman","year":"2016","journal-title":"J Neurosci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/s0896-6273(00)81127-7","article-title":"Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform","volume":"3","author":"Ishihara","year":"1999","journal-title":"Neuron"},{"key":"B71","doi-asserted-by":"publisher","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy","volume":"30","author":"Brunden","year":"2010","journal-title":"J Neurosci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/s0002-9440(10)64296-4","article-title":"Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation","volume":"5","author":"Cash","year":"2003","journal-title":"Am J Pathol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1523\/JNEUROSCI.0188-12.2012","article-title":"Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027","volume":"21","author":"Barten","year":"2012","journal-title":"J Neurosci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1083\/jcb.200605187","article-title":"Tau-dependent microtubule disassembly initiated by prefibrillar \u03b2-amyloid","volume":"4","author":"King","year":"2006","journal-title":"J Cell Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1073\/pnas.092136199","article-title":"Tau is essential to \u03b2-amyloid-induced neurotoxicity","volume":"9","author":"Rapoport","year":"2002","journal-title":"PNAS"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1038\/emboj.2013.207","article-title":"Amyloid-\u03b2 oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin","volume":"22","author":"Zempel","year":"2013","journal-title":"EMBO J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"11938","DOI":"10.1523\/JNEUROSCI.2357-10.2010","article-title":"A\u03b2 oligomers cause localized Ca2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines","volume":"36","author":"Zempel","year":"2010","journal-title":"J Neurosci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"12171","DOI":"10.1073\/pnas.2034961100","article-title":"Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease","volume":"100","author":"Trushina","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"B79","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","article-title":"Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro","volume":"24","author":"Trushina","year":"2004","journal-title":"Mol Cell Biol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.nbd.2005.12.007","article-title":"Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons","volume":"2","author":"Chang","year":"2006","journal-title":"Neurobiol Dis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1523\/JNEUROSCI.0106-08.2008","article-title":"N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking","volume":"11","author":"Orr","year":"2008","journal-title":"J Neurosci"},{"key":"B82","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","article-title":"Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules","volume":"1","author":"Gauthier","year":"2004","journal-title":"Cell"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1093\/hmg\/ddv224","article-title":"Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease","volume":"24","author":"Fern\u00e1ndez-Nogales","year":"2015","journal-title":"Hum Mol Genet."},{"key":"B84","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40478-019-0764-9","article-title":"A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington's disease patients","volume":"7","author":"Liu","year":"2019","journal-title":"Acta Neuropathol Commun."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1179069518772380","DOI":"10.1177\/1179069518772380","article-title":"Tau: a common denominator and therapeutic target for neurodegenerative disorders","volume":"12","author":"Maxan","year":"2018","journal-title":"J Exp Neurosci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's disease collaborative research group","volume":"72","year":"1993","journal-title":"Cell"},{"key":"B87","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/hmg\/10.10.1049","article-title":"Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release","volume":"10","author":"Jana","year":"2001","journal-title":"Hum Mol Genet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1097-2765(04)00151-0","article-title":"Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins","volume":"14","author":"Venkatraman","year":"2004","journal-title":"Mol Cell."},{"key":"B90","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science."},{"key":"B91","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/WCO.0b013e3283550c97","article-title":"Huntington's disease","volume":"25","author":"Ha","year":"2012","journal-title":"Curr Opin Neurol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2217\/nmt.12.34","article-title":"Monitoring Huntington's disease progression through preclinical and early stages","volume":"2","author":"Tang","year":"2012","journal-title":"Neurodegener Dis Manag."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.neurobiolaging.2014.12.006","article-title":"Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals","volume":"36","author":"Winder-Rhodes","year":"2015","journal-title":"Neurobiol Aging."},{"key":"B94","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer's disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci Transl Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3233\/JAD-170129","article-title":"PET tau and amyloid-\u03b2 burden in mild Alzheimer's Disease: divergent relationship with age, cognition, and cerebrospinal fluid biomarkers","volume":"60","author":"Koychev","year":"2017","journal-title":"J Alzheimers Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jnc.13719","article-title":"Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease","volume":"139","author":"Rodrigues","year":"2016","journal-title":"J Neurochem."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J Clin Invest."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/mds.22204","article-title":"Association of corticobasal degeneration and Huntington's disease: can tau aggregates protect huntingtin toxicity?","volume":"24","author":"Caparros-Lefebvre","year":"2009","journal-title":"Mov Disord."},{"key":"B99","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JHD-140111","article-title":"The co-occurrence of Alzheimer's disease and Huntington's disease: a neuropathological study of 15 elderly Huntington's disease subjects","volume":"3","author":"Davis","year":"2014","journal-title":"J Huntingtons Dis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1532-5415.1988.tb01807.x","article-title":"The coexistence and differentiation of late onset Huntington's Disease and Alzheimer's Disease: a case report and review of the literature","volume":"36","author":"Moss","year":"1988","journal-title":"J Am Geriatr Soc."},{"key":"B101","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0140-6736(86)92134-3","article-title":"Defective brain microtubule assembly in Alzheimer's disease","volume":"2","author":"Iqbal","year":"1986","journal-title":"Lancet."},{"key":"B103","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Bu\u00e9e","year":"2000","journal-title":"Brain Res Brain Res Rev."},{"key":"B104","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc Natl Acad Sci USA."},{"key":"B105","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1074\/jbc.M111.306472","article-title":"Evidence for irreversible inhibition of glycogen synthase kinase-3\u03b2 by tideglusib","volume":"287","author":"Dom\u00ednguez","year":"2012","journal-title":"J Biol Chem."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archneur.63.1.49","article-title":"A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease","volume":"63","author":"Reisberg","year":"2006","journal-title":"Arch Neurol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fneur.2013.00083","article-title":"The importance of tau phosphorylation for neurodegenerative diseases","volume":"4","author":"Noble","year":"2013","journal-title":"Front Neurol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0168-0102(99)00026-7","article-title":"Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain","volume":"34","author":"Lee","year":"1999","journal-title":"Neurosci Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2990.2006.00795.x","article-title":"Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration","volume":"33","author":"Leroy","year":"2007","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/emboj\/20.1.27","article-title":"Decreased nuclear \u03b2-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3\u03b2 conditional transgenic mice","volume":"20","author":"Lucas","year":"2001","journal-title":"EMBO J."},{"key":"B113","doi-asserted-by":"publisher","first-page":"41340","DOI":"10.1074\/jbc.M006219200","article-title":"Glycogen synthase kinase-3\u03b2 phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice","volume":"275","author":"Spittaels","year":"2000","journal-title":"J Biol Chem."},{"key":"B114","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2353\/ajpath.2008.070904","article-title":"Amyloid activates GSK-3\u03b2 to aggravate neuronal tauopathy in bigenic mice","volume":"172","author":"Terwel","year":"2008","journal-title":"Am J Pathol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell."},{"key":"B116","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J Comp Neurol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.phrs.2016.02.007","article-title":"The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-\u00df1-42 oligomers in mice","volume":"106","author":"Leggio","year":"2016","journal-title":"Pharmacol Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0002-9440(10)63347-0","article-title":"Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick type C mice","volume":"165","author":"Zhang","year":"2004","journal-title":"Am J Clin Pathol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1523\/JNEUROSCI.22-15-06515.2002","article-title":"Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann\u2013Pick Type C murine model","volume":"22","author":"Bu","year":"2002","journal-title":"J Neurosci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/j.1471-4159.2006.04139.x","article-title":"Chronic lithium administration to FTDP-17 tau and GSK-3\u03b2 overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert","volume":"99","author":"Engel","year":"2006","journal-title":"J Neurochem."},{"key":"B121","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/JAD-2003-5405","article-title":"Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model","volume":"5","author":"P\u00e9rez","year":"2003","journal-title":"J Alzheimers Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2353\/ajpath.2007.061178","article-title":"Lithium reduces tau phosphorylation but not A\u03b2 or working memory deficits in a transgenic model with both plaques and tangles","volume":"170","author":"Caccamo","year":"2007","journal-title":"Am J Pathol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B124","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer's disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J Alzheimers Dis."},{"key":"B125","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3233\/JAD-150437","article-title":"Lithium as a Treatment for Alzheimer's Disease: a systematic review and meta-analysis","volume":"48","author":"Matsunaga","year":"2015","journal-title":"J Alzheimers Dis."},{"key":"B126","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0140-6736(73)93285-6","article-title":"Baclofen and lithium in Huntington's chorea","volume":"2","author":"And\u00e9n","year":"1973","journal-title":"Lancet."},{"key":"B127","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1600-0447.1977.tb03561.x","article-title":"Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial","volume":"56","author":"Vestergaard","year":"1977","journal-title":"Acta Psychiatr Scand."},{"key":"B128","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0361-9230(03)00141-2","article-title":"Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation","volume":"61","author":"Wood","year":"2003","journal-title":"Brain Res Bull."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.7150\/ijbs.9898","article-title":"Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?","volume":"10","author":"Scheuing","year":"2014","journal-title":"Int J Biol Sci."},{"key":"B130","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejphar.2008.07.021","article-title":"Lithium-induced suppression of transcription repressor NRSF\/REST: effects on the dysfunction of neuronal differentiation by ethanol","volume":"593","author":"Ishii","year":"2008","journal-title":"Eur J Pharmacol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0306-4522(02)00573-0","article-title":"Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities","volume":"116","author":"Kopnisky","year":"2003","journal-title":"Neuroscience."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1073\/pnas.95.5.2642","article-title":"Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-d-aspartate receptor-mediated calcium influx","volume":"95","author":"Nonaka","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B133","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s002130100871","article-title":"Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain","volume":"158","author":"Fukumoto","year":"2001","journal-title":"Psychopharmacol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.mp.4001042","article-title":"Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats","volume":"7","author":"Hellweg","year":"2002","journal-title":"Mol Psychiatry."},{"key":"B135","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jpsychires.2009.11.002","article-title":"Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain","volume":"44","author":"Jornada","year":"2010","journal-title":"J Psychiatr Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/sj.mp.4002099","article-title":"The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons","volume":"14","author":"Yasuda","year":"2009","journal-title":"Mol Psychiatry."},{"key":"B137","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41386-019-0556-8","article-title":"Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study","volume":"45","author":"Akkouh","year":"2020","journal-title":"Neuropsychopharmacology."},{"key":"B138","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10571-013-9907-x","article-title":"Lithium's gene expression profile, relevance to neuroprotection a cDNA microarray study","volume":"33","author":"Farah","year":"2013","journal-title":"Cell Mol Neurobiol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/0019-5545.105522","article-title":"Off label use of lithium in the treatment of Huntington's disease: a case series","volume":"55","author":"Danivas","year":"2013","journal-title":"Indian J Psychiatry."},{"key":"B140","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/00048677509159834","article-title":"A double blind trial of lithium carbonate and haloperidol in Huntington's chorea","volume":"9","author":"Leonard","year":"1975","journal-title":"Aust N Z J Psychiatry."},{"key":"B141","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1093\/hmg\/ddu119","article-title":"Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain","volume":"23","author":"Lim","year":"2014","journal-title":"Hum Mol Genet."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0002-9440(10)62486-8","article-title":"Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease","volume":"166","author":"Tanimukai","year":"2005","journal-title":"Am J Pathol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.nbd.2009.08.012","article-title":"Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: Role in excitotoxicity","volume":"36","author":"Xifr\u00f3","year":"2009","journal-title":"Neurobiol Dis."},{"key":"B144","doi-asserted-by":"publisher","first-page":"e49838","DOI":"10.1371\/journal.pone.0049838","article-title":"Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175","volume":"7","author":"Menalled","year":"2012","journal-title":"PLoS ONE."},{"key":"B145","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0968-0004(99)01375-4","article-title":"Regulation of protein kinase cascades by protein phosphatase 2A","volume":"24","author":"Millward","year":"1999","journal-title":"Trends Biochem Sci."},{"key":"B146","doi-asserted-by":"publisher","first-page":"38193","DOI":"10.1074\/jbc.M102621200","article-title":"Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice","volume":"276","author":"Kins","year":"2001","journal-title":"J Biol Chem."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e48843","DOI":"10.15252\/embr.201948843","article-title":"Protein phosphatase PP2A regulates microtubule orientation and dendrite pruning in Drosophila","volume":"21","author":"Rui","year":"2020","journal-title":"EMBO Rep."},{"key":"B148","doi-asserted-by":"publisher","first-page":"9293","DOI":"10.1523\/JNEUROSCI.1740-06.2006","article-title":"The B\u2032 protein phosphatase 2A regulatory subunit well-rounded regulates synaptic growth and cytoskeletal stability at the drosophila neuromuscular junction","volume":"26","author":"Viquez","year":"2006","journal-title":"J Neurosci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13041-019-0469-9","article-title":"A protein phosphatase 2A deficit in the hippocampal CA1 area impairs memory extinction","volume":"12","author":"Wang","year":"2019","journal-title":"Mol Brain."},{"key":"B150","doi-asserted-by":"publisher","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00841-6","article-title":"Direct activation of protein phosphatase 2A (PP2A) by tricyclic sulfonamides ameliorates Alzheimer's disease pathogenesis in cell and animal models","author":"Wei","year":"2020","journal-title":"Neurotherapeutics."},{"key":"B152","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.febslet.2004.04.047","article-title":"Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration","volume":"566","author":"Li","year":"2004","journal-title":"FEBS Lett."},{"key":"B153","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2010.01.008","article-title":"Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice","volume":"65","author":"Milnerwood","year":"2010","journal-title":"Neuron."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/npp.2009.64","article-title":"Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation","volume":"34","author":"Wu","year":"2009","journal-title":"Neuropsychopharmacology."},{"key":"B155","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-7091-0579-5_14","article-title":"The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease","volume":"68","author":"Beister","year":"2004","journal-title":"J Neural Transm Suppl."},{"key":"B156","first-page":"1353","article-title":"Clinical experience with risperidone and memantine in the treatment of Huntington's disease","volume":"98","author":"Cankurtaran","year":"2006","journal-title":"J Natl Med Assoc."},{"key":"B157","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol Ther."},{"key":"B158","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/10409238.2016.1143913","article-title":"PP2A as a master regulator of the cell cycle","volume":"51","author":"Wlodarchak","year":"2016","journal-title":"Crit Rev Biochem Mol Biol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1756-6606-2-33","article-title":"Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease","volume":"2","author":"Pineda","year":"2009","journal-title":"Mol Brain."},{"key":"B160","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fneur.2013.00114","article-title":"Are tau aggregates toxic or protective in tauopathies?","volume":"4","author":"Cowan","year":"2013","journal-title":"Front Neurol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","article-title":"Staging of alzheimer's disease-related neurofibrillary changes","volume":"16","author":"Braak","year":"1995","journal-title":"Neurobiol Aging."},{"key":"B162","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-3-7091-6467-9_11","article-title":"Evolution of neuronal changes in the course of Alzheimer's disease","volume-title":"Ageing and Dementia","author":"Braak","year":"1998"},{"key":"B163","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3233\/JAD-2008-14402","article-title":"Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly","volume":"14","author":"Iqbal","year":"2008","journal-title":"J Alzheimers Dis."},{"key":"B164","doi-asserted-by":"publisher","first-page":"P161","DOI":"10.1016\/j.jalz.2014.04.150","article-title":"Granular tau oligomer as toxic tau aggregation form in AD","volume":"10","author":"Takashima","year":"2014","journal-title":"Alzheimers Dement."},{"key":"B165","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2478\/s13380-012-0032-y","article-title":"Soluble forms of tau are toxic in Alzheimer's disease","volume":"3","author":"Kopeikina","year":"2012","journal-title":"Transl Neurosci."},{"key":"B166","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1523\/JNEUROSCI.0587-07.2007","article-title":"Accumulation of pathological tau species and memory loss in a conditional model of tauopathy","volume":"27","author":"Berger","year":"2007","journal-title":"J Neurosci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/2051-5960-1-82","article-title":"Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice","volume":"1","author":"Hoffmann","year":"2013","journal-title":"Acta Neuropathol Commun."},{"key":"B168","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1326-6-39","article-title":"Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice","volume":"6","author":"Lasagna-Reeves","year":"2011","journal-title":"Mol Neurodegener."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cne.23234","article-title":"Synaptic alterations in the rTg4510 mouse model of tauopathy","volume":"521","author":"Kopeikina","year":"2013","journal-title":"J Comp Neurol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.expneurol.2009.07.029","article-title":"Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs","volume":"223","author":"Rocher","year":"2010","journal-title":"Exp Neurol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","article-title":"Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model","volume":"53","author":"Yoshiyama","year":"2007","journal-title":"Neuron."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1093\/brain\/awt088","article-title":"The influence of phospho-\u03c4 on dendritic spines of cortical pyramidal neurons in patients with Alzheimer's disease","volume":"136","author":"Merino-Serrais","year":"2013","journal-title":"Brain."},{"key":"B173","doi-asserted-by":"publisher","first-page":"12997","DOI":"10.1523\/JNEUROSCI.5284-12.2013","article-title":"Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's Disease","volume":"33","author":"Murmu","year":"2013","journal-title":"J Neurosci."},{"key":"B174","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.neuropharm.2010.01.016","article-title":"Tau protein and tau aggregation inhibitors","volume":"59","author":"Bulic","year":"2010","journal-title":"Neuropharmacology."},{"key":"B175","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1074\/jbc.M112.436006","article-title":"Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation","volume":"288","author":"Crowe","year":"2013","journal-title":"J Biol Chem."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3233\/JAD-181001","article-title":"Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers: a plausible key to understanding failure of a clinical trial for Alzheimer's disease","volume":"68","author":"Soeda","year":"2019","journal-title":"J Alzheimers Dis."},{"key":"B177","doi-asserted-by":"publisher","first-page":"e52389","DOI":"10.1371\/journal.pone.0052389","article-title":"Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice","volume":"7","author":"Hosokawa","year":"2012","journal-title":"PLoS ONE"},{"key":"B178","doi-asserted-by":"publisher","first-page":"11109","DOI":"10.1523\/JNEUROSCI.0895-12.2012","article-title":"Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models","volume":"32","author":"Sontag","year":"2012","journal-title":"J Neurosci."},{"key":"B179","doi-asserted-by":"publisher","first-page":"P592","DOI":"10.1016\/j.jalz.2017.07.227","article-title":"Preclinical characterization of an antibody [LY3303560] targeting aggregated tau","volume":"13","author":"Alam","year":"2017","journal-title":"Alzheimers Dement."},{"key":"B180","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.3233\/JAD-132477","article-title":"Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds","volume":"40","author":"Castillo-Carranza","year":"2014","journal-title":"J Alzheimers Dis."},{"key":"B181","doi-asserted-by":"publisher","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS ONE."},{"key":"B182","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40478-019-0765-8","article-title":"A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease","volume":"7","author":"Smith","year":"2019","journal-title":"Acta Neuropathol Commun."},{"key":"B183","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12974-014-0152-0","article-title":"Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis","volume":"11","author":"Selenica","year":"2014","journal-title":"J Neuroinflammation."},{"key":"B184","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1523\/JNEUROSCI.3192-13.2014","article-title":"Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles","volume":"34","author":"Castillo-Carranza","year":"2014","journal-title":"J Neurosci."},{"key":"B185","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3233\/JAD-140996","article-title":"N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization","volume":"43","author":"Paholikova","year":"2015","journal-title":"J Alzheimers Dis."},{"key":"B186","unstructured":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease2020"},{"key":"B187","unstructured":"Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease2013"},{"key":"B188","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fnins.2014.00235","article-title":"New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease","volume":"8","author":"Fuller","year":"2014","journal-title":"Front Neurosci."},{"key":"B189","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1073\/pnas.1607215114","article-title":"Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation","volume":"114","author":"McEwan","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B190","doi-asserted-by":"publisher","first-page":"e0135774","DOI":"10.1371\/journal.pone.0135774","article-title":"Passive immunization in JNPL3 transgenic mice using an array of phospho-tau specific antibodies","volume":"10","author":"d'Abramo","year":"2015","journal-title":"PLoS ONE"},{"key":"B191","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E","article-title":"Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau","volume":"48","author":"Jicha","year":"1997","journal-title":"J Neurosci Res."},{"key":"B192","unstructured":"Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease2020"},{"key":"B193","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1016\/j.celrep.2018.03.021","article-title":"Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways","volume":"22","author":"Evans","year":"2018","journal-title":"Cell Rep."},{"key":"B194","doi-asserted-by":"publisher","first-page":"12845","DOI":"10.1074\/jbc.M808759200","article-title":"Propagation of tau misfolding from the outside to the inside of a cell","volume":"284","author":"Frost","year":"2009","journal-title":"J Biol Chem."},{"key":"B195","doi-asserted-by":"publisher","first-page":"14893","DOI":"10.1074\/jbc.M115.652693","article-title":"Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation","volume":"290","author":"Mirbaha","year":"2015","journal-title":"J Biol Chem."},{"key":"B196","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00401-018-1855-6","article-title":"Tau seeding activity begins in the transentorhinal\/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART","volume":"136","author":"Kaufman","year":"2018","journal-title":"Acta Neuropathol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/19336896.2016.1223003","article-title":"Tunneling nanotubes: a possible highway in the spreading of tau and other prion-like proteins in neurodegenerative diseases","volume":"10","author":"Abounit","year":"2016","journal-title":"Prion."},{"key":"B198","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.celrep.2015.04.043","article-title":"Synaptic contacts enhance cell-to-cell tau pathology propagation","volume":"11","author":"Calafate","year":"2015","journal-title":"Cell Rep."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1074\/jbc.M112.394528","article-title":"Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons","volume":"288","author":"Wu","year":"2013","journal-title":"J Biol Chem."},{"key":"B200","doi-asserted-by":"publisher","first-page":"19440","DOI":"10.1074\/jbc.M112.346072","article-title":"Trans-cellular propagation of tau aggregation by fibrillar species","volume":"287","author":"Kfoury","year":"2012","journal-title":"J Biol Chem."},{"key":"B201","doi-asserted-by":"publisher","first-page":"e105010","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting A\u03b2 and tau in Alzheimer's disease","volume":"144","author":"Plotkin","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B202","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrd4708","article-title":"Stem-cell discovery platforms yield first clinical candidates","volume":"14","author":"Mullard","year":"2015","journal-title":"Nat Rev Drug Disc."},{"key":"B203","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","article-title":"Human secreted tau increases amyloid-beta production","volume":"36","author":"Bright","year":"2015","journal-title":"Neurobiol Aging."},{"key":"B204","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"key":"B205","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"key":"B206","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/acn3.176","article-title":"Anti-tau antibody reduces insoluble tau and decreases brain atrophy","volume":"2","author":"Yanamandra","year":"2015","journal-title":"Ann Clin Transl Neurol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","article-title":"A walk through tau therapeutic strategies","volume":"7","author":"Jadhav","year":"2019","journal-title":"Acta Neuropathol Commun."},{"key":"B209","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.parkreldis.2011.06.010","article-title":"Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease","volume":"17","author":"Constantinescu","year":"2011","journal-title":"Parkinsonism Relat Disord."},{"key":"B210","doi-asserted-by":"publisher","first-page":"e0172762","DOI":"10.1371\/journal.pone.0172762","article-title":"Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?","volume":"12","author":"Niemel\u00e4","year":"2017","journal-title":"PLoS ONE."},{"key":"B211","doi-asserted-by":"publisher","first-page":"e0163479","DOI":"10.1371\/journal.pone.0163479","article-title":"Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's disease","volume":"11","author":"Rodrigues","year":"2016","journal-title":"PLoS ONE."},{"key":"B212","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"104569","DOI":"10.1016\/j.nbd.2019.104569","article-title":"Antibody-based therapies for Huntington's disease: current status and future directions","volume":"132","author":"Denis","year":"2019","journal-title":"Neurobiol Dis."},{"key":"B214","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-62703-541-5_15","article-title":"Methods for conjugating antibodies to nanocarriers","volume":"1045","author":"Wagh","year":"2013","journal-title":"Methods Mol Biol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"104943","DOI":"10.1016\/j.nbd.2020.104943","article-title":"Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: implications for the treatment of Huntington's disease","volume":"141","author":"Bartl","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B216","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ana.24174","article-title":"Mutant huntingtin is present in neuronal grafts in Huntington disease patients","volume":"76","author":"Cicchetti","year":"2014","journal-title":"Ann Neurol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"104941","DOI":"10.1016\/j.nbd.2020.104941","article-title":"Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates","volume":"141","author":"Gosset","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B218","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00401-016-1582-9","article-title":"Human-to-mouse prion-like propagation of mutant huntingtin protein","volume":"132","author":"Jeon","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3389\/fnins.2017.00647","article-title":"The evidence for the spread and seeding capacities of the mutant huntingtin protein in in vitro systems and their therapeutic implications","volume":"11","author":"Masnata","year":"2017","journal-title":"Front Neurosci."},{"key":"B220","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00401-019-01973-6","article-title":"Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms","volume":"137","author":"Masnata","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"104951","DOI":"10.1016\/j.nbd.2020.104951","article-title":"Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates","volume":"141","author":"Maxan","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-0787-4","article-title":"Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology","author":"Rieux","year":"2020","journal-title":"Mol Psychiatry."},{"key":"B223","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.baga.2017.02.038","article-title":"Tau pathology in Huntington's disease: a brief in vivo PET-imaging report","volume":"8","author":"Giehl","year":"2017","journal-title":"Basal Ganglia"},{"key":"B224","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","article-title":"In vivo quantification of neurofibrillary tangles with [18F]MK-6240","volume":"10","author":"Pascoal","year":"2018","journal-title":"Alzheimer's Res Ther."},{"key":"B225","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1002\/hbm.23535","article-title":"Differential microstructural and morphological abnormalities in mild cognitive impairment and Alzheimer's disease: evidence from cortical and deep gray matter","volume":"38","author":"Gong","year":"2017","journal-title":"Hum Brain Mapp."},{"key":"B226","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s004010050420","article-title":"Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease","volume":"91","author":"Praprotnik","year":"1996","journal-title":"Acta Neuropathol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0197-4580(90)90059-9","article-title":"Quantitative assessment of cortical synaptic density in Alzheimer's disease","volume":"11","author":"Scheff","year":"1990","journal-title":"Neurobiol Aging."},{"key":"B228","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0896-6273(03)00569-5","article-title":"Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport","volume":"40","author":"Szebenyi","year":"2003","journal-title":"Neuron."},{"key":"B229","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1073\/pnas.0406361102","article-title":"Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B230","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial","volume":"77","author":"Tsai","year":"2019","journal-title":"JAMA Neurol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2174\/156720507783018208","article-title":"NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell","volume":"4","author":"Gozes","year":"2007","journal-title":"Curr Alzheimer Res."},{"key":"B232","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.neuroscience.2008.11.021","article-title":"Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL\/6 mouse","volume":"158","author":"Sari","year":"2009","journal-title":"Neuroscience."},{"key":"B233","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000348347","article-title":"A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement Geriatr Cogn Disord."},{"key":"B234","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/hmg\/ddq521","article-title":"Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases","volume":"20","author":"Sudo","year":"2011","journal-title":"Hum Mol Genet."},{"key":"B235","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00221-016-4836-9","article-title":"Impairment of mitochondria dynamics by human A53T \u03b1-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease","volume":"235","author":"Melo","year":"2017","journal-title":"Exp Brain Res."},{"key":"B236","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/jpet.107.129551","article-title":"Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model","volume":"323","author":"Vulih-Shultzman","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"B237","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol Biol Cell."},{"key":"B239","doi-asserted-by":"publisher","first-page":"e000504","DOI":"10.1136\/esmoopen-2019-000504","article-title":"How I treat metastatic triple-negative breast cancer","volume":"4","author":"Caparica","year":"2019","journal-title":"ESMO Open"},{"key":"B240","first-page":"195","article-title":"Epothilone B induces glioblastoma cell death via survivin down-regulation","volume":"30","author":"Quick","year":"2008","journal-title":"Exp Oncol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fncel.2018.00226","article-title":"Repositioning microtubule stabilizing drugs for brain disorders","volume":"12","author":"Varidaki","year":"2018","journal-title":"Front Cell Neurosci."},{"key":"B242","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ana.10163","article-title":"Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation","volume":"51","author":"Hayashi","year":"2002","journal-title":"Ann Neurol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"e76409","DOI":"10.1371\/journal.pone.0076409","article-title":"A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered tau function","volume":"8","author":"Iyer","year":"2013","journal-title":"PLoS ONE."},{"key":"B244","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/1531-8249(200012)48:6","article-title":"A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies","volume":"48","author":"Spillantini","year":"2000","journal-title":"Ann Neurol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s00415-004-0489-x","article-title":"Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies","volume":"251","author":"Stanford","year":"2004","journal-title":"J Neurol."},{"key":"B246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2007.04.006","article-title":"Functional MAPT haplotypes: Bridging the gap between genotype and neuropathology","volume":"27","author":"Caffrey","year":"2007","journal-title":"Neurobiol Dis."},{"key":"B247","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.neuron.2016.04.042","article-title":"Increased 4R-tau induces pathological changes in a human-tau mouse model","volume":"90","author":"Schoch","year":"2016","journal-title":"Neuron."},{"key":"B248","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nm.2613","article-title":"Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export","volume":"18","author":"Lei","year":"2012","journal-title":"Nat Med."},{"key":"B250","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0304-3940(99)00964-7","article-title":"Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice","volume":"279","author":"Ikegami","year":"2000","journal-title":"Neurosci Lett."},{"key":"B251","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci Transl Med."},{"key":"B252","unstructured":"A Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Extension, to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease2020"},{"key":"B253","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med."},{"key":"B254","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/d41573-019-00018-7","article-title":"Pioneering antisense drug heads into pivotal trials for Huntington disease","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B255","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/dna.2019.5188","article-title":"Therapeutic antisense targeting of huntingtin","volume":"39","author":"Smith","year":"2019","journal-title":"DNA Cell Biol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3389\/fncel.2019.00574","article-title":"Altered levels and isoforms of tau and nuclear membrane invaginations in Huntington's disease","volume":"13","author":"Fern\u00e1ndez-Nogales","year":"2019","journal-title":"Front Cell Neurosci."},{"key":"B257","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/molecules23061302","article-title":"A Half-century history of applications of antisense oligonucleotides in medicine, agriculture and forestry: we should continue the journey","volume":"23","author":"Oberemok","year":"2018","journal-title":"Molecules."},{"key":"B258","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s004010050477","article-title":"Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease","volume":"91","author":"Mena","year":"1996","journal-title":"Acta Neuropathol."},{"key":"B259","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1046\/j.1471-4159.1997.69041709.x","article-title":"Characterization of in vitro glycation sites of tau","volume":"69","author":"Nacharaju","year":"1997","journal-title":"J Neurochem."},{"key":"B260","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1021\/bi047982v","article-title":"Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease","volume":"44","author":"Reynolds","year":"2005","journal-title":"Biochemistry."},{"key":"B261","doi-asserted-by":"publisher","first-page":"10825","DOI":"10.1074\/jbc.M512786200","article-title":"Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation","volume":"281","author":"Cripps","year":"2006","journal-title":"J Biol Chem."},{"key":"B262","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.neuint.2010.12.023","article-title":"Post-translational modifications of tau protein: Implications for Alzheimer's disease","volume":"58","author":"Martin","year":"2011","journal-title":"Neurochem Int."},{"key":"B263","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI200420640","article-title":"Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology","volume":"114","author":"Rissman","year":"2004","journal-title":"J Clin Invest."},{"key":"B264","unstructured":"BoxerA A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy2018"},{"key":"B265","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1471-4159.2000.0750436.x","article-title":"Impaired proteasome function in Alzheimer's disease","volume":"75","author":"Keller","year":"2000","journal-title":"J Neurochem."},{"key":"B266","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nm.4011","article-title":"Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling","volume":"22","author":"Myeku","year":"2016","journal-title":"Nat Med."},{"key":"B267","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3233\/JAD-2006-9S336","article-title":"Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system","volume":"9","author":"van Leeuwen","year":"2006","journal-title":"J Alzheimers Dis."},{"key":"B268","doi-asserted-by":"publisher","first-page":"E7176","DOI":"10.1073\/pnas.1522332112","article-title":"cAMP-induced phosphorylation of 26S proteasomes on Rpn6\/PSMD11 enhances their activity and the degradation of misfolded proteins","volume":"112","author":"Lokireddy","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B269","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fnmol.2014.00077","article-title":"Ubiquitin\u2013proteasome system involvement in Huntington's disease","volume":"7","author":"Ortega","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"B270","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science."},{"key":"B271","doi-asserted-by":"publisher","first-page":"e5128","DOI":"10.1371\/journal.pone.0005128","article-title":"The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6\/2 transgenic mouse model of Huntington's Disease","volume":"4","author":"Bett","year":"2009","journal-title":"PLoS ONE."},{"key":"B272","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1523\/JNEUROSCI.5673-09.2010","article-title":"Acute polyglutamine expression in inducible mouse model unravels ubiquitin\/proteasome system impairment and permanent recovery attributable to aggregate formation","volume":"30","author":"Ortega","year":"2010","journal-title":"J Neurosci."},{"key":"B273","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.febslet.2013.11.023","article-title":"Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies","volume":"588","author":"Schipper-Krom","year":"2014","journal-title":"FEBS Lett."},{"key":"B274","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-016-0092-5","article-title":"Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons","volume":"11","author":"Nekrasov","year":"2016","journal-title":"Mol Neurodegener."},{"key":"B275","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1371\/journal.pone.0000238","article-title":"Proteasome activator enhances survival of Huntington's disease neuronal model cells","volume":"2","author":"Seo","year":"2007","journal-title":"PLoS ONE."},{"key":"B276","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"key":"B277","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.580732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T20:19:19Z","timestamp":1618431559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.580732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":277,"alternative-id":["10.3389\/fneur.2020.580732"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.580732","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"article-number":"580732"}}